CTI BioPharma Corp.
CTIC · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.26 | -0.04 | -3.16 | -0.05 |
| FCF Yield | -15.41% | -37.98% | -18.43% | -30.37% |
| EV / EBITDA | -8.88 | -2.19 | -4.06 | -1.94 |
| Quality | ||||
| ROIC | -84.24% | -178.59% | -105.62% | -132.02% |
| Gross Margin | 93.49% | 0.00% | 0.00% | 100.00% |
| Cash Conversion Ratio | 0.87 | 0.87 | 0.80 | 0.70 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -100.00% | -100.00% | -48.95% |
| Free Cash Flow Growth | -25.10% | -101.05% | -51.76% | 30.20% |
| Safety | ||||
| Net Debt / EBITDA | -0.24 | 0.16 | 0.74 | 0.50 |
| Interest Coverage | -6.07 | -39.47 | -46.29 | -26.73 |
| Efficiency | ||||
| Inventory Turnover | 4.79 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -28.33 | -8,821.21 | -142.26 | 0.00 |